<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>597</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>15297401</PubmedId>
            <Abstract>The importance of CD8(+) cytolytic T cells for protection from viral infection and in the generation of immune responses against tumors has been well established. In contrast, the role of CD4(+) T-helper cells in human infection and in cancer immunity has yet to be clearly defined. In this pilot study, we show that immunization of three resected, high-risk metastatic melanoma patients with a T-helper epitope derived from the melanoma differentiation antigen, melanoma antigen recognized by T cells-1, results in CD4(+) T-cell immune responses. Immune reactivity to that epitope was detected by DR4-peptide tetramer staining, and enzyme-linked immunospot assay of fresh and restimulated CD4(+) T cells from patients over the course of the 12-month vaccine regimen. The postvaccine CD4(+) T cells exhibited a mixed T-helper 1/T-helper 2 phenotype, proliferated in response to the antigen and promiscuously recognized the peptide epitope bound to different human leukocyte antigen-DRbeta alleles. For 1 DRbeta1*0401(+) patient, antigen-specific CD4(+) T cells recognized human leukocyte antigen-matched antigen-expressing tumor cells, secreted granzyme B, and also exhibited cytolysis that was MHC class II-restricted. These data establish the immunogenicity of a class II epitope derived from a melanoma-associated antigen and support the inclusion of class II peptides in future melanoma vaccine therapies.</Abstract>
            <ArticleYear>2004</ArticleYear>
            <ArticlePages>5004-13</ArticlePages>
            <ArticleTitle>Immune responses to a class II helper peptide epitope in patients with stage III/IV resected melanoma.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Wong</LastName>
                    <ForeName>Raymond</ForeName>
                </Author>
                <Author>
                    <LastName>Lau</LastName>
                    <ForeName>Roy</ForeName>
                </Author>
                <Author>
                    <LastName>Chang</LastName>
                    <ForeName>Jenny</ForeName>
                </Author>
                <Author>
                    <LastName>Kuus-Reichel</LastName>
                    <ForeName>Tina</ForeName>
                </Author>
                <Author>
                    <LastName>Brichard</LastName>
                    <ForeName>Vincent</ForeName>
                </Author>
                <Author>
                    <LastName>Bruck</LastName>
                    <ForeName>Claudine</ForeName>
                </Author>
                <Author>
                    <LastName>Weber</LastName>
                    <ForeName>Jeffrey</ForeName>
                </Author>
            </Authors>
            <Affiliations>Department of Medicine, Keck/University of Southern California School of Medicine, Los Angeles, California 90089, USA.</Affiliations>
            <ArticleChemicalList>Antigens, Neoplasm;CD3 Complex;CD4 Antigens;Cancer Vaccines;Epitopes;HLA Antigens;HLA-DR Antigens;Lipid A;MART-1 Antigen;MLANA protein, human;Neoplasm Proteins;Peptides;Saponins;saponin QA-21V1;GZMB protein, human;Granzymes;Serine Endopeptidases;monophosphoryl lipid A</ArticleChemicalList>
            <ArticleMeshHeadingsList>Age Factors; Alleles; Antigens, Neoplasm; CD3 Complex(biosynthesis); CD4 Antigens(biosynthesis); CD4-Positive T-Lymphocytes(immunology); CD8-Positive T-Lymphocytes(immunology); Cancer Vaccines(chemistry; therapeutic use); Cell Line, Tumor; Cell Proliferation; Dendritic Cells(cytology; metabolism); Enzyme-Linked Immunosorbent Assay; Epitopes(chemistry); Female; Flow Cytometry; Granzymes; HLA Antigens(chemistry); HLA-DR Antigens(genetics); Humans; Immunotherapy(methods); Leukocytes, Mononuclear(immunology; metabolism); Lipid A(analogs &amp; derivatives; pharmacology); Lymphocytes(metabolism); MART-1 Antigen; Male; Melanoma(metabolism; surgery; therapy); Microscopy, Fluorescence; Neoplasm Proteins(chemistry); Peptides(chemistry); Pilot Projects; Saponins(pharmacology); Serine Endopeptidases(chemistry); T-Lymphocytes(metabolism); Th1 Cells(immunology); Th2 Cells(immunology); Time Factors; Treatment Outcome</ArticleMeshHeadingsList>
            <Journal>
                <Volume>10</Volume>
                <Issue>15</Issue>
                <Title>Clinical cancer research : an official journal of the American Association for Cancer Research</Title>
                <Issn>1078-0432</Issn>
                <MedlineTa>Clin Cancer Res</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>MART-1&lt;sub&gt;51-73&lt;/sub&gt;</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>RNGYRALMDKSLHVGTQCALTRR</LinearSequence>
                        <StartingPosition>51</StartingPosition>
                        <EndingPosition>73</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q16655.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>9606</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <EpitopeId>54996</EpitopeId>
                <ReferenceStartingPosition>51</ReferenceStartingPosition>
                <ReferenceEndingPosition>73</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 2A</LocationOfData>
                        <TCellId>5531</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of cancer</InVivoProcessType>
                                <DiseaseState>DOID:8923</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <Adjuvant>AS02 (SBAS2)</Adjuvant>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>RNGYRALMDKSLHVGTQCALTRR</LinearSequence>
                                            <StartingPosition>51</StartingPosition>
                                            <EndingPosition>73</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>Q16655.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>MART-1&lt;sub&gt;51-73&lt;/sub&gt;</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>AS02 (SBAS2)</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>Patients were immunized once monthly for the first 6 months, then once every 3 months for the subsequent 6 months, for a total of eight vaccinations over 1 year.</DoseSchedule>
                            </SecondInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell CD4+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>PBMC</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>341</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>MART-1&lt;sub&gt;51-73&lt;/sub&gt;</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>RNGYRALMDKSLHVGTQCALTRR</LinearSequence>
                                        <StartingPosition>51</StartingPosition>
                                        <EndingPosition>73</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q16655.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>2</NumberOfSubjectsResponded>
                            <ResponseFrequency>66.7</ResponseFrequency>
                            <AssayComments>Positive values were shown at 6 months post-vaccine time point, with very low prevaccine background levels.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 3B</LocationOfData>
                        <TCellId>5534</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of cancer</InVivoProcessType>
                                <DiseaseState>DOID:8923</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <Adjuvant>AS02 (SBAS2)</Adjuvant>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>RNGYRALMDKSLHVGTQCALTRR</LinearSequence>
                                            <StartingPosition>51</StartingPosition>
                                            <EndingPosition>73</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>Q16655.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>MART-1&lt;sub&gt;51-73&lt;/sub&gt;</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>AS02 (SBAS2)</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>Patients were immunized once monthly for the first 6 months, then once every 3 months for the subsequent 6 months, for a total of eight vaccinations over 1 year.</DoseSchedule>
                            </SecondInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                                <ResponderCellType>PBMC</ResponderCellType>
                                <StimulatorCellType>PBMC</StimulatorCellType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>RNGYRALMDKSLHVGTQCALTRR</LinearSequence>
                                            <StartingPosition>51</StartingPosition>
                                            <EndingPosition>73</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>Q16655.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                            <ImmunizationComments>Subsequent booster immunizations were given at months 9 and 12 of the vaccine regimen and resulted in increased recall responses observed at or after the twelfth month of the trial for each patient.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell CD4+</CellType>
                            <CellCultureConditions>Short Term Restimulated</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>PBMC</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>341</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>MART-1&lt;sub&gt;51-73&lt;/sub&gt;</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>RNGYRALMDKSLHVGTQCALTRR</LinearSequence>
                                        <StartingPosition>51</StartingPosition>
                                        <EndingPosition>73</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q16655.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>51</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>3</NumberOfSubjectsResponded>
                            <ResponseFrequency>100</ResponseFrequency>
                            <AssayComments>Positive values were shown at 6 month and 12 month post-vaccine time points, with very low prevaccine background levels.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 7</LocationOfData>
                        <TCellId>5538</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of cancer</InVivoProcessType>
                                <DiseaseState>DOID:8923</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <Adjuvant>AS02 (SBAS2)</Adjuvant>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>RNGYRALMDKSLHVGTQCALTRR</LinearSequence>
                                            <StartingPosition>51</StartingPosition>
                                            <EndingPosition>73</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>Q16655.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>MART-1&lt;sub&gt;51-73&lt;/sub&gt;</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>AS02 (SBAS2)</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>Patients were immunized once monthly for the first 6 months, then once every 3 months for the subsequent 6 months, for a total of eight vaccinations over 1 year.</DoseSchedule>
                            </SecondInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                                <ResponderCellType>PBMC</ResponderCellType>
                                <StimulatorCellType>Dendritic cell</StimulatorCellType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>RNGYRALMDKSLHVGTQCALTRR</LinearSequence>
                                            <StartingPosition>51</StartingPosition>
                                            <EndingPosition>73</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>Q16655.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell CD4+</CellType>
                            <CellCultureConditions>Short Term Restimulated</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellType>Other</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>N</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>341</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>MART-1&lt;sub&gt;51-73&lt;/sub&gt;</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>RNGYRALMDKSLHVGTQCALTRR</LinearSequence>
                                        <StartingPosition>51</StartingPosition>
                                        <EndingPosition>73</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q16655.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>143</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Data for other two immunized patients not shown. Positive responses were shown for 6 and 12 months post-vaccination.  The T2.DR4 (DRB1*0401+) cell line and was used as a target cell.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <TCellId>5536</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of cancer</InVivoProcessType>
                                <DiseaseState>DOID:8923</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <Adjuvant>AS02 (SBAS2)</Adjuvant>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>RNGYRALMDKSLHVGTQCALTRR</LinearSequence>
                                            <StartingPosition>51</StartingPosition>
                                            <EndingPosition>73</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>Q16655.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>MART-1&lt;sub&gt;51-73&lt;/sub&gt;</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>AS02 (SBAS2)</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>Patients were immunized once monthly for the first 6 months, then once every 3 months for the subsequent 6 months, for a total of eight vaccinations over 1 year.</DoseSchedule>
                            </SecondInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                                <ResponderCellType>PBMC</ResponderCellType>
                                <StimulatorCellType>Dendritic cell</StimulatorCellType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>RNGYRALMDKSLHVGTQCALTRR</LinearSequence>
                                            <StartingPosition>51</StartingPosition>
                                            <EndingPosition>73</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>Q16655.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell CD4+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellType>Other</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>N</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>341</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>MART-1&lt;sub&gt;51-73&lt;/sub&gt;</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>RNGYRALMDKSLHVGTQCALTRR</LinearSequence>
                                        <StartingPosition>51</StartingPosition>
                                        <EndingPosition>73</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q16655.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Four DRB1*0401+/MART-1+ melanoma cell lines were used as target cells, including 624mel, 697mel, 1102mel, and 1359mel.  Positive responses were shown at 6 and 12 months post-vaccination.  Data for other two immunized patients not shown.  IL-5 responses were not detected.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 3A</LocationOfData>
                        <TCellId>5533</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of cancer</InVivoProcessType>
                                <DiseaseState>DOID:8923</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <Adjuvant>AS02 (SBAS2)</Adjuvant>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>RNGYRALMDKSLHVGTQCALTRR</LinearSequence>
                                            <StartingPosition>51</StartingPosition>
                                            <EndingPosition>73</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>Q16655.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>MART-1&lt;sub&gt;51-73&lt;/sub&gt;</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>AS02 (SBAS2)</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>Patients were immunized once monthly for the first 6 months, then once every 3 months for the subsequent 6 months, for a total of eight vaccinations over 1 year.</DoseSchedule>
                            </SecondInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                                <ResponderCellType>PBMC</ResponderCellType>
                                <StimulatorCellType>PBMC</StimulatorCellType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>RNGYRALMDKSLHVGTQCALTRR</LinearSequence>
                                            <StartingPosition>51</StartingPosition>
                                            <EndingPosition>73</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>Q16655.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                            <ImmunizationComments>Subsequent booster immunizations were given at months 9 and 12 of the vaccine regimen and resulted in increased recall responses observed at or after the twelfth month of the trial for each patient.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell CD4+</CellType>
                            <CellCultureConditions>Short Term Restimulated</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>PBMC</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>341</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>MART-1&lt;sub&gt;51-73&lt;/sub&gt;</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>RNGYRALMDKSLHVGTQCALTRR</LinearSequence>
                                        <StartingPosition>51</StartingPosition>
                                        <EndingPosition>73</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q16655.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>3</NumberOfSubjectsResponded>
                            <ResponseFrequency>100</ResponseFrequency>
                            <AssayComments>Positive values were shown at 6 month and 12 month post-vaccine time points, with very low prevaccine background levels.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 6A</LocationOfData>
                        <TCellId>5537</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of cancer</InVivoProcessType>
                                <DiseaseState>DOID:8923</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <Adjuvant>AS02 (SBAS2)</Adjuvant>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>RNGYRALMDKSLHVGTQCALTRR</LinearSequence>
                                            <StartingPosition>51</StartingPosition>
                                            <EndingPosition>73</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>Q16655.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>MART-1&lt;sub&gt;51-73&lt;/sub&gt;</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>AS02 (SBAS2)</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>Patients were immunized once monthly for the first 6 months, then once every 3 months for the subsequent 6 months, for a total of eight vaccinations over 1 year.</DoseSchedule>
                            </SecondInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                                <ResponderCellType>PBMC</ResponderCellType>
                                <StimulatorCellType>Dendritic cell</StimulatorCellType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>RNGYRALMDKSLHVGTQCALTRR</LinearSequence>
                                            <StartingPosition>51</StartingPosition>
                                            <EndingPosition>73</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>Q16655.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell CD4+</CellType>
                            <CellCultureConditions>Short Term Restimulated</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellType>Other</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>N</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>341</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>MART-1&lt;sub&gt;51-73&lt;/sub&gt;</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>RNGYRALMDKSLHVGTQCALTRR</LinearSequence>
                                        <StartingPosition>51</StartingPosition>
                                        <EndingPosition>73</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q16655.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Data for other two immunized patients not shown.  Antigen-specific lysis was detected with maximal specific lysis at approximately 30% at effector:target ratios of 60:, which was completely abrogatedby the addition of an anti-MHC class II antibody.  The addition of an anti-Fas antibody to the assay did not inhibit cell-mediated lysis  The T2.DR4 (DRB1*0401+) cell line was used as a target cell.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 2B</LocationOfData>
                        <TCellId>5532</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of cancer</InVivoProcessType>
                                <DiseaseState>DOID:8923</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <Adjuvant>AS02 (SBAS2)</Adjuvant>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>RNGYRALMDKSLHVGTQCALTRR</LinearSequence>
                                            <StartingPosition>51</StartingPosition>
                                            <EndingPosition>73</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>Q16655.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>MART-1&lt;sub&gt;51-73&lt;/sub&gt;</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>AS02 (SBAS2)</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>Patients were immunized once monthly for the first 6 months, then once every 3 months for the subsequent 6 months, for a total of eight vaccinations over 1 year.</DoseSchedule>
                            </SecondInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell CD4+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>PBMC</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>341</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>MART-1&lt;sub&gt;51-73&lt;/sub&gt;</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>RNGYRALMDKSLHVGTQCALTRR</LinearSequence>
                                        <StartingPosition>51</StartingPosition>
                                        <EndingPosition>73</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q16655.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>51</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>2</NumberOfSubjectsResponded>
                            <ResponseFrequency>66.7</ResponseFrequency>
                            <AssayComments>Positive values were shown at 6 months post-vaccine time point, with very low prevaccine background levels.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 1B</LocationOfData>
                        <TCellId>5530</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of cancer</InVivoProcessType>
                                <DiseaseState>DOID:8923</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <Adjuvant>AS02 (SBAS2)</Adjuvant>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>RNGYRALMDKSLHVGTQCALTRR</LinearSequence>
                                            <StartingPosition>51</StartingPosition>
                                            <EndingPosition>73</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>Q16655.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>MART-1&lt;sub&gt;51-73&lt;/sub&gt;</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>AS02 (SBAS2)</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>Patients were immunized once monthly for the first 6 months, then once every 3 months for the subsequent 6 months, for a total of eight vaccinations over 1 year.</DoseSchedule>
                            </SecondInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                                <ResponderCellType>PBMC</ResponderCellType>
                                <StimulatorCellType>PBMC</StimulatorCellType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>RNGYRALMDKSLHVGTQCALTRR</LinearSequence>
                                            <StartingPosition>51</StartingPosition>
                                            <EndingPosition>73</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>Q16655.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>PBMC</CellType>
                            <CellCultureConditions>Short Term Restimulated</CellCultureConditions>
                        </EffectorCells>
                        <MhcAllele>
                            <MhcAlleleId>341</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>MART-1&lt;sub&gt;51-73&lt;/sub&gt;</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>RNGYRALMDKSLHVGTQCALTRR</LinearSequence>
                                        <StartingPosition>51</StartingPosition>
                                        <EndingPosition>73</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q16655.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>47</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <QuantitativeMeasurement>10.54</QuantitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Data is presented for one patient, but not for the other two immunized patients.  Data analysis was performedthrough sequential gating on CD3+ and CD4+ populations toobtain the percentage of tetramer+ in the total CD4+ T-cellpopulation.  The response was shown at post-vaccine time points of 6 and 12 months.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 7</LocationOfData>
                        <TCellId>5539</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of cancer</InVivoProcessType>
                                <DiseaseState>DOID:8923</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <Adjuvant>AS02 (SBAS2)</Adjuvant>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>RNGYRALMDKSLHVGTQCALTRR</LinearSequence>
                                            <StartingPosition>51</StartingPosition>
                                            <EndingPosition>73</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>Q16655.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>MART-1&lt;sub&gt;51-73&lt;/sub&gt;</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>AS02 (SBAS2)</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>Patients were immunized once monthly for the first 6 months, then once every 3 months for the subsequent 6 months, for a total of eight vaccinations over 1 year.</DoseSchedule>
                            </SecondInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                                <ResponderCellType>PBMC</ResponderCellType>
                                <StimulatorCellType>Dendritic cell</StimulatorCellType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>RNGYRALMDKSLHVGTQCALTRR</LinearSequence>
                                            <StartingPosition>51</StartingPosition>
                                            <EndingPosition>73</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>Q16655.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell CD4+</CellType>
                            <CellCultureConditions>Short Term Restimulated</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>PBMC</CellType>
                            <CellCultureConditions>Short Term Restimulated</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>341</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>MART-1&lt;sub&gt;51-73&lt;/sub&gt;</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>RNGYRALMDKSLHVGTQCALTRR</LinearSequence>
                                        <StartingPosition>51</StartingPosition>
                                        <EndingPosition>73</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q16655.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>143</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Data for other two immunized patients not shown. Positive responses were shown for 6 and 12 months post-vaccination.  The T2.DR4 (DRB1*0401+) cell line and was used as a target cell.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 1A</LocationOfData>
                        <TCellId>5529</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of cancer</InVivoProcessType>
                                <DiseaseState>DOID:8923</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <Adjuvant>AS02 (SBAS2)</Adjuvant>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>RNGYRALMDKSLHVGTQCALTRR</LinearSequence>
                                            <StartingPosition>51</StartingPosition>
                                            <EndingPosition>73</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>Q16655.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>MART-1&lt;sub&gt;51-73&lt;/sub&gt;</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>AS02 (SBAS2)</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>Patients were immunized once monthly for the first 6 months, then once every 3 months for the subsequent 6 months, for a total of eight vaccinations over 1 year.</DoseSchedule>
                            </SecondInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>PBMC</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <MhcAllele>
                            <MhcAlleleId>341</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>MART-1&lt;sub&gt;51-73&lt;/sub&gt;</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>RNGYRALMDKSLHVGTQCALTRR</LinearSequence>
                                        <StartingPosition>51</StartingPosition>
                                        <EndingPosition>73</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q16655.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>47</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <QuantitativeMeasurement>0.15</QuantitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Data is presented for one patient, but not for the other two immunized patients.  Data analysis was performedthrough sequential gating on CD3+ and CD4+ populations toobtain the percentage of tetramer+ in the total CD4+ T-cellpopulation.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <TCellId>5535</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of cancer</InVivoProcessType>
                                <DiseaseState>DOID:8923</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <Adjuvant>AS02 (SBAS2)</Adjuvant>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>RNGYRALMDKSLHVGTQCALTRR</LinearSequence>
                                            <StartingPosition>51</StartingPosition>
                                            <EndingPosition>73</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>Q16655.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>MART-1&lt;sub&gt;51-73&lt;/sub&gt;</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>AS02 (SBAS2)</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>Patients were immunized once monthly for the first 6 months, then once every 3 months for the subsequent 6 months, for a total of eight vaccinations over 1 year.</DoseSchedule>
                            </SecondInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>PBMC</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>PBMC</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>341</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>MART-1&lt;sub&gt;51-73&lt;/sub&gt;</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>RNGYRALMDKSLHVGTQCALTRR</LinearSequence>
                                        <StartingPosition>51</StartingPosition>
                                        <EndingPosition>73</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q16655.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>69</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>3</NumberOfSubjectsResponded>
                            <ResponseFrequency>100</ResponseFrequency>
                            <AssayComments>Postvaccine (6 months) samples for all 3 of the patients demonstrated higher proliferation to MART-151–73 than respective prevaccine samples.  Assay involved CD8+-depleted PBMCs were stimulated with peptide for 5 days.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

